» Articles » PMID: 33361098

Longitudinal Course of Clinical Lung Clearance Index in Children with Cystic Fibrosis

Overview
Journal Eur Respir J
Specialty Pulmonary Medicine
Date 2020 Dec 28
PMID 33361098
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although the lung clearance index (LCI) is a sensitive marker of small airway disease in individuals with cystic fibrosis (CF), less is known about longitudinal changes in LCI during routine clinical surveillance. Here, our objectives were to describe the longitudinal course of LCI in children with CF during routine clinical surveillance and assess influencing factors.

Methods: Children with CF aged 3-18 years performed LCI measurements every 3 months as part of routine clinical care between 2011 and 2018. We recorded clinical data at every visit. We used a multilevel mixed effect model to determine changes in LCI over time and identify clinical factors that influence LCI course.

Results: We collected LCI measurements from 1204 visits (3603 trials) in 78 participants, of which 907 visits had acceptable LCI data. The average unadjusted increase in LCI for the entire population was 0.29 (95% CI 0.20-0.38) LCI units·year. The increase in LCI was more pronounced in adolescence (0.41 (95% CI 0.27-0.54) LCI units·year). Colonisation with either or , pulmonary exacerbations, CF-related diabetes and bronchopulmonary aspergillosis were associated with a higher increase in LCI over time. Adjusting for clinical risk factors reduced the increase in LCI over time to 0.24 (95% CI 0.16-0.33) LCI units·year.

Conclusions: LCI measured during routine clinical surveillance is associated with underlying disease progression in children with CF. An increased change in LCI over time should prompt further diagnostic intervention.

Citing Articles

Multiple-breath washout to detect lung disease in patients with inborn errors of immunity.

Busack L, Thee S, Liu Y, Allomba C, Ziegahn N, Tosolini A ERJ Open Res. 2024; 10(2).

PMID: 38469376 PMC: 10926008. DOI: 10.1183/23120541.01019-2023.


Association of Oxygen Therapy with the Natural Disease Progression of Cystic Fibrosis: A Multi-State Model of the European Cystic Fibrosis Society Patient Registry.

Gambazza S, Orenti A, Pizzamiglio G, Zolin A, Colombo C, Laquintana D Ther Clin Risk Manag. 2023; 19:255-267.

PMID: 36935771 PMC: 10022450. DOI: 10.2147/TCRM.S391476.


Isolated abnormal FEF75% detects unsuspected bronchiolar obstruction in CF children.

Masson V, Nussbaum E, Gelb A, Tashkin D, Randhawa I, Nadel J Pediatr Res. 2023; 94(3):1051-1056.

PMID: 36914809 DOI: 10.1038/s41390-023-02532-2.


Breath detection algorithms affect multiple-breath washout outcomes in pre-school and school age children.

Oestreich M, Wyler F, Frauchiger B, Latzin P, Ramsey K PLoS One. 2022; 17(10):e0275866.

PMID: 36240198 PMC: 9565421. DOI: 10.1371/journal.pone.0275866.


Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study.

Mall M, Brugha R, Gartner S, Legg J, Moeller A, Mondejar-Lopez P Am J Respir Crit Care Med. 2022; 206(11):1361-1369.

PMID: 35816621 PMC: 9746869. DOI: 10.1164/rccm.202202-0392OC.